Pharvaris N.V. (PHVS)
Verdict history · PHVS
Every call Verdix has made on PHVS.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
The prior WAIT called for either CHAPTER‑3 data or a decisive price move, and neither has fired. What changed is the weight of regulatory validation: FDA acceptance and EMA validation arrived in the interim, lifting the estimated probability of eventual approval enough that two bullish archetypes now see staying uninvested as the larger risk. The three neutrals accept this logic for existing holders but will not commit fresh capital, producing a BALANCED rather than a BUY.
See methodology for how verdicts are produced. Full track record →
The panel’s split verdict on PHVS — and where they disagree.
The case for and against roughly balance — no clear edge at today's price.
NASDAQ · Health Care / Biotechnology · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BalancedMEDIUM confidence
Why
Six archetypes debate a pre‑revenue biotech trading at 7x net cash ahead of binary Phase 3 data. Two see enough probability‑weighted upside to hold; three refuse to commit capital without a margin of safety; one rejects the business entirely. The panel lands on BALANCED: existing positions stay, new money waits for the catalyst.Level to watch
Key resistance 36.6+0.9% from 36.27
Next catalyst
Catalyst this quarter: Positive CHAPTER‑3 topline results would flip the call to BUY, potentially sending the stock toward $48–72; negative data likely drives it below $20 toward net cash.The panel's take
Verdict: BALANCED · Conviction: MEDIUM · Last price: 36.27 · Changed from WAIT
Panel: 2 Bullish · 3 Neutral · 1 Bearish → BALANCED
What changed since 2026-08-15:
- Price: 35.14 → 36.27 (+3.22%)
- Panel: 1 of 6 → 2 of 6 now Bullish — composition also changed: added The Scuttlebutt Growth Investor; removed The Asymmetric Bargainer
- Trigger: BUY on positive CHAPTER‑3 topline data plus either (a) a decisive weekly close above $36.93 on strong volume, confirming the breakout, or (b) a pullback into the $30.71–$33.09 support zone. SELL on negative Phase 3 data or a weekly close below the weekly EMA20 at $32.32.
- Verdict: WAIT → BALANCED
The prior WAIT called for either CHAPTER‑3 data or a decisive price move, and neither has fired. What changed is the weight of regulatory validation: FDA acceptance and EMA validation arrived in the interim, lifting the estimated probability of eventual approval enough that two bullish archetypes now see staying uninvested as the larger risk. The three neutrals accept this logic for existing holders but will not commit fresh capital, producing a BALANCED rather than a BUY.
The prior WAIT trigger (CHAPTER‑3 data + breakout above $36.93 or pullback to $30.71–$33.09) has not fired — the data is still pending and price sits between the two entry zones — yet the verdict shifts to BALANCED because the two bullish voices (The Intrinsic-Value Modeler, The Disruptive-Innovation Seeker) now see sufficient probability‑weighted upside from the FDA acceptance, EMA validation, and analyst target upgrades that staying uninvested risks missing the move. The three neutrals (The GARP Operator, The Forensic Skeptic, The Scuttlebutt Growth Investor) keep it from BUY: they accept the binary risk is unresolved and do not advocate selling, but they will not commit fresh capital to a pre‑revenue name trading at 7x net cash with no margin of safety. The Activist Catalyst's lone bearish vote objects to the business model entirely. The result is BALANCED — existing holders stay, new money waits for the catalyst.
Key levels
Key levels · PHVS
USD · as of 2026-08-22Analyst consensus target 48.34 USD · range 35.46–75.1
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance sits at $36.60–$36.93: the upper bound is the 52‑week and all‑time swing high tested repeatedly in August 2026, and a weekly close above it would confirm a Stage 2 continuation breakout. Key support begins at $33.09 (23.6% Fibonacci retracement of the $20.65–$36.93 rally), reinforced by $33.00 as former horizontal resistance turned first pullback support. The weekly EMA20 at $32.32 is the technical scout's first line of trend defence. Deeper, $30.71 marks the 38.2% Fib, while $28.79 (50% Fib) and $28.61 (weekly EMA50) form a cluster that would invalidate the intermediate Stage 2 thesis if broken. The 61.8% retracement at $26.87 aligns with the monthly EMA20, making it the last key support before the trend structure fully unwinds. The analyst consensus target of $48.34 sits roughly 33% above the current price, consistent with the bullish voices' probability‑weighted upside.
What legendary investors think
We ran Pharvaris N.V. past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The GARP OperatorGrowth (GARP)⚫ NeutralLow
Signal: A pre‑revenue biotech with zero earnings, zero revenue, and no PEG ratio cannot be evaluated through a framework that requires reasonable growth at a reasonable price — the single most important number simply does not exist. Conviction: Conviction stays low because the central metric that anchors every GARP decision, a PEG ratio grounded in actual profits, is absent and will remain absent until well after a potential 2027 launch.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: At $36.27 the stock trades at 7x net cash of $5.17 per share, meaning the market has already priced in successful Phase 3 data and FDA approval before either has occurred. Conviction: The absence of any calculable margin of safety for a binary event keeps conviction muted despite a clean balance sheet and a cash runway into 2028.
The Intrinsic-Value ModelerValuation/DCF🟢 BullishLow
Signal: A probability‑weighted DCF using a 50% approval likelihood, $1.2B peak sales, and a 15% cost of capital produces an estimated value of $48 per share, implying 32% upside from the current price. Conviction: Multiple independent derisking events — FDA acceptance of the NDA, EMA validation of the MAA, and a string of analyst target upgrades — push conviction above neutral even before the pivotal CHAPTER‑3 data arrives.
The Disruptive-Innovation SeekerDisruptive Innovation🟢 BullishMed
Signal: FDA acceptance of the NDA with a PDUFA date in April 2027 places deucrictibant on the cusp of the S‑curve, where an oral therapy could disrupt the injection‑dependent HAE treatment paradigm for the first time. Conviction: Conviction is tempered by the reality that this is a single binary catalyst rather than an exponential growth curve, and the TAM is niche — a rare‑disease market — rather than a platform that spawns multiple adjacent opportunities.
The Activist CatalystActivist/Capital Allocation🔴 BearishLow
Signal: The business scores 1 out of 10 on quality: no approved product, no revenue, no pricing power, no competitive moat, and $147M in annual cash burn with nothing to offset it. Conviction: The framework simply cannot underwrite a company with zero revenue, zero approved products, and no durable competitive advantage — the position is bearish on the business model itself, not on timing.
The Scuttlebutt Growth InvestorGrowth/Management⚫ NeutralLow
Signal: The 15‑point checklist yields only 9 passable items out of 15, and every criterion tied to commercial capability — sales organization, profit margins, margin improvement — is unanswerable for a pre‑revenue company. Conviction: Buying a stock that cannot complete the checklist is a mistake in the original analysis, and the framework offers no reason to override that judgment while the commercial story remains entirely unproven.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six archetypes agree the stock is a binary bet on CHAPTER‑3 Phase 3 data, expected this quarter, and the April 2027 PDUFA date.
- All recognize the balance sheet is clean: $363M cash, effectively zero debt, cash runway into 2028.
- All note that $1.7M in insider selling over 90 days with zero insider purchases is a cautionary flag.
- All acknowledge the stock is near its 52‑week high ($36.93) with RSI at 68.9, approaching overbought territory.
The real debate
- The Intrinsic-Value Modeler and The Disruptive-Innovation Seeker treat FDA acceptance and EMA validation as sufficient independent derisking to justify staying invested ahead of the catalyst, while The Forensic Skeptic and The GARP Operator counter that 7x net cash means the market has already priced in success, leaving no cushion for disappointment.
- The Activist Catalyst rejects the business model outright — no moat, no product, no revenue — whereas even the neutral voices concede that if deucrictibant works, the commercial opportunity in HAE is real and the oral differentiation is genuine.
The question it comes down to: Does the probability‑weighted upside from pending Phase 3 data justify holding through a binary catalyst when the stock already trades at 7x net cash near its all‑time high?
The bottom line
- Catalyst this quarter: Positive CHAPTER‑3 topline results would flip the call to BUY, potentially sending the stock toward $48–72; negative data likely drives it below $20 toward net cash.
- Breakout to confirm: A decisive weekly close above $36.93 on strong volume would confirm the bullish structure and support a BUY even without the data in hand.
- Historical accumulation zone: A pullback into $30.71–$33.09 combined with positive CHAPTER‑3 data would strengthen the bull case by adding a margin of safety.
- PDUFA April 2027: Even after Phase 3 data, FDA approval is not automatic; the PDUFA date remains the next major regulatory gate and a distinct risk event.
- Insider activity to watch: Continued insider selling with zero purchases ahead of the catalyst would erode conviction further across the panel.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in PHVS · PHVS verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated